Current Environment: Production

Medical Services

Programs & Services

Languages

  • English
  • Greek

Education

Medical School

University of Athens Medical School

2008, Athens, Greece

Internship

Pediatics

Children's Medical Center at Dallas

2012, Dallas, TX

Graduate School

PhD, Immunopharmacology

University of Athens Medical School

2013, Athens, Greece

Residency

Pediatrics

Children's Medical Center at Dallas

2014, Dallas, TX

Fellowship

Harvard Neonatal-Perinatal Medicine Training Program

2016, Boston, MA

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Neonatal-Perinatal Medicine)

Professional History

Asimenia Angelidou, MD, PhD obtained her medical degree and doctoral degree in Immunopharmacology from the University of Athens in Greece. She completed her pediatric residency training at the University of Texas Southwestern and Children’s Medical Center at Dallas, TX, and her clinical fellowship in Neonatal-Perinatal Medicine at the Harvard Combined Training Program in Neonatology where she also served as Chief Fellow. She is currently an attending Neonatologist at the Boston Children’s Hospital Neonatal Intensive Care Unit and Instructor at Harvard Medical School.Dr. Angelidou has a special interest in neonatal trained immunity. Under the mentorship of Drs. Ofer Levy and Mihai Netea, she focused on newborn innate immune ontogeny and the role of vaccine-induced "heterologous protection" against unrelated pathogens, research for which she received the Marshall Klaus Perinatal Research Award from the American Academy of Pediatrics.

Publications

  1. Safety and implementation of phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns. J Clin Invest. 2025 Apr 03. View Abstract

  2. Product and trial design considerations on the path towards a vaccine to combat opioid overdose. NPJ Vaccines. 2025 Feb 19; 10(1):35. View Abstract

  3. Trends in Neonatal Vaccination: A Ten-year Retrospective Study in a Large Delivery Center. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S97-S100. View Abstract

  4. Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference. Vaccine. 2025 Jan 01; 43(Pt 2):126477. View Abstract

  5. Predictive gene expression signature diagnoses neonatal sepsis before clinical presentation. EBioMedicine. 2024 Dec; 110:105411. View Abstract

  6. Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns. medRxiv. 2024 Oct 17. View Abstract

  7. DNA Methylation signatures underpinning blood neutrophil to lymphocyte ratio during first week of human life. Nat Commun. 2024 Sep 17; 15(1):8167. View Abstract

  8. Breastfeeding and Neonatal Age Influence Neutrophil-Driven Ontogeny of Blood Cell Populations in the First Week of Human Life. J Immunol Res. 2024; 2024:1117796. View Abstract

  9. Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl. Vaccine. 2024 Oct 24; 42(24):126082. View Abstract

  10. Proteomics-Based Mapping of Bronchopulmonary Dysplasia-Associated Changes in Noninvasively Accessible Oral Secretions. J Pediatr. 2024 Jul; 270:113774. View Abstract

  11. Precision Vaccine Adjuvants for Older Adults: A Scoping Review. Clin Infect Dis. 2022 08 15; 75(Suppl 1):S72-S80. View Abstract

  12. Precision Vaccines: Lessons Learned From the Coronavirus Pandemic. Clin Infect Dis. 2022 08 15; 75(Suppl 1):S1. View Abstract

  13. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection. Clin Infect Dis. 2022 08 15; 75(Suppl 1):S130-S135. View Abstract

  14. Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus Vaccination in Pregnancy: Implications for Maternal and Infant Immunity. Clin Infect Dis. 2022 08 15; 75(Suppl 1):S37-S45. View Abstract

  15. The Effects of COVID-19 Hospital Practices on Breastfeeding Initiation and Duration Postdischarge. Breastfeed Med. 2022 09; 17(9):736-744. View Abstract

  16. Bacille Calmette-Guérin vaccine reprograms human neonatal lipid metabolism in vivo and in vitro. Cell Rep. 2022 05 03; 39(5):110772. View Abstract

  17. A quality improvement initiative to reduce acid-suppressing medication exposure in the NICU. J Perinatol. 2022 08; 42(8):1118-1125. View Abstract

  18. BCG vaccine's off-target effects on allergic, inflammatory, and autoimmune diseases: Worth another shot? J Allergy Clin Immunol. 2022 01; 149(1):51-54. View Abstract

  19. Human Newborn Monocytes Demonstrate Distinct BCG-Induced Primary and Trained Innate Cytokine Production and Metabolic Activation In Vitro. Front Immunol. 2021; 12:674334. View Abstract

  20. Leveraging the Massachusetts perinatal quality collaborative to address the COVID-19 pandemic among diverse populations. J Perinatol. 2021 11; 41(11):2674-2683. View Abstract

  21. Association of Maternal Perinatal SARS-CoV-2 Infection With Neonatal Outcomes During the COVID-19 Pandemic in Massachusetts. JAMA Netw Open. 2021 04 01; 4(4):e217523. View Abstract

  22. Vaccination of Term and Preterm Infants. Neoreviews. 2020 12; 21(12):e817-e827. View Abstract

  23. Integrative Metabolomics to Identify Molecular Signatures of Responses to Vaccines and Infections. Metabolites. 2020 Nov 30; 10(12). View Abstract

  24. Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life. Front Immunol. 2020; 11:578505. View Abstract

  25. BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny. Front Microbiol. 2020; 11:332. View Abstract

  26. Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. Vaccine. 2020 02 24; 38(9):2229-2240. View Abstract

  27. Immunometabolic approaches to prevent, detect, and treat neonatal sepsis. Pediatr Res. 2020 01; 87(2):399-405. View Abstract

  28. Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. Nat Commun. 2019 03 12; 10(1):1092. View Abstract

  29. Is There More to Zika? Complex Cardiac Disease in a Case of Congenital Zika Syndrome. Neonatology. 2018; 113(2):177-182. View Abstract

  30. Implementation of a Guideline to Decrease Use of Acid-Suppressing Medications in the NICU. Pediatrics. 2017 Dec; 140(6). View Abstract

  31. Neurotensin and CRH interactions augment human mast cell activation. PLoS One. 2012; 7(11):e48934. View Abstract

  32. Perinatal stress, brain inflammation and risk of autism-review and proposal. BMC Pediatr. 2012 Jul 02; 12:89. View Abstract

  33. Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. Int Arch Allergy Immunol. 2012; 159(1):23-32. View Abstract

  34. Contribution of stress to asthma worsening through mast cell activation. Ann Allergy Asthma Immunol. 2012 Jul; 109(1):14-9. View Abstract

  35. IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. PLoS One. 2012; 7(3):e33271. View Abstract

  36. Mast cells in allergic and inflammatory diseases. Curr Pharm Des. 2012; 18(16):2261-77. View Abstract

  37. Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol. 2012 Feb; 132(2):324-9. View Abstract

  38. Brief report: "allergic symptoms" in children with Autism Spectrum Disorders. More than meets the eye? J Autism Dev Disord. 2011 Nov; 41(11):1579-85. View Abstract

  39. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol. 2011 Jun; 127(6):1522-31.e8. View Abstract

  40. Mast cell activation and autism. Biochim Biophys Acta. 2012 Jan; 1822(1):34-41. View Abstract

  41. Mast cells and inflammation. Biochim Biophys Acta. 2012 Jan; 1822(1):21-33. View Abstract

  42. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J Neuroinflammation. 2010 Nov 17; 7:80. View Abstract

  43. Increased affected skin gene expression and serum levels of thymic stromal lymphopoietin in atopic dermatitis. Ann Allergy Asthma Immunol. 2010 Nov; 105(5):403-4. View Abstract

  44. Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. Int J Immunopathol Pharmacol. 2010 Oct-Dec; 23(4):1015-20. View Abstract

  45. Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation. 2010 Aug 23; 7:48. View Abstract

  46. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4448-53. View Abstract

In the Boston Children’s Hospital (BCH) Neonatal Intensive Care Unit (NICU) our philosophy is to ensure that every patient receives the best care for the best possible outcomes. We consider our “patient” to be the baby and the family; we are constantly striving to serve the needs of both. This requires a team based approach with all members being essential. The future of any society depends on its ability to foster the health and well-being of the next generation. This is the reason I chose to become a pediatrician. As a neonatologist at Boston Children’s Hospital, I am devoted to serving our smallest and most vulnerable patients by integrating highly specialized clinical care with rigorous translational science. I put great emphasis on establishing trusting relationships with families and integrating parental values in decision-making.

BESbswy